BRCA1 and ovarian cancer: Therefore, we focus on BRCA1/2-related mechanisms of carcinogenesis for high-grade serous epithelial cancer (HGSC), as high-grade ovarian carcinomas are most likely to demonstrate the greatest benefit from PARPi therapeutics among ovarian cancers.